Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Xiaodong Mo, He Huang, Feng Chen, Yi Luo, Jia Chen, Erlie Jiang, Yicheng Zhang, Linghui Xia, Chengwei Luo Luo, Xinchuan Chen, Nainong Li, Ming Jiang, Sujun Gao, Dongqin Yang, Qingli Zuo, Yimin Chen, Li Yao, Pan Liang, Depei Wu

Blood (2024) 144 (Supplement 1): 99.

https://doi.org/10.1182/blood-2024-193191

Published: 2024

Journal Articles

Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Blood (2024) 144 (Supplement 1): 3838.

https://doi.org/10.1182/blood-2024-201926

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2024-201137

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

QI Tan, Zheng Li, Sifan Chen, Qingya Cui, Mengyun Li, Ye Zhao, Feng Chen, Depei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2023-185976

Published: 2023

Journal Articles

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

Mao Jin, Sicheng Ai, Tao You, Xiao Ma, Feng Chen, Caixia Li, Zhengming Jin, Depei Wu, Haiwen Huang

Blood (2023) 142 (Supplement 1): 6215.

https://doi.org/10.1182/blood-2023-186001

Published: 2023

Journal Articles

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xinglu Zhou

Blood (2023) 142 (Supplement 1): 3139.

https://doi.org/10.1182/blood-2023-185241

Published: 2023

Journal Articles

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Zhuang Kang, Feng Chen, Yi Lin, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xingguo Liu, Xinglu Zhou, Wenbin Li

Blood (2022) 140 (Supplement 1): 12064.

https://doi.org/10.1182/blood-2022-166776

Published: 2022

Journal Articles

Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Lijuan Deng, Tianheng He, Di Mei, Yongjing Tang, Changyu Lu, Xian Zhang, Meixiang Zhang, Feng Chen, Xiaopei Wang, Jun Zhu, Yuqin Song

Blood (2022) 140 (Supplement 1): 9459–9460.

https://doi.org/10.1182/blood-2022-164632

Published: 2022

Journal Articles

Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy

Serageldin Kamel, Li-Wei Chen, Gregory Ravizzini, Ho-Feng Chen, Joo Schmidt, Sairah Ahmed, Ranjit Nair, Raphael E Steiner, Branko Cuglievan, Yago Nieto, Roberto N. Miranda, Penny Fang, Jillian R. Gunther, Chelsea C. Pinnix, Michael Wang, Tinsu Pan, Hun Ju Lee

Blood (2021) 138 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2021-153517

Published: 2021

Journal Articles

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Feng Chen, MD PhD, Depei Wu, MD PhD, Ran Wang, MD, Xianghua Huang, MD PhD, Xiaozhong Li, MD PhD, Chaoxing Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5696.

https://doi.org/10.1182/blood-2019-128121

Published: 2019

Journal Articles

Comparison of Autologous Stem Cell Transplantation Versus Haplo-Identical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission

Jia Chen, MD, Lingyi Yang, MD, Yi Fan, MD, Xiuli Wang, MD PhD, Yang Xu, MD PhD, Feng Chen, MD PhD, Ying Wang, MDPhD, Xiang Zhang, Tiemei Song, Su-Ning Chen, MD PhD, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 4595.

https://doi.org/10.1182/blood.V130.Suppl_1.4595.4595

Published: 2017

Journal Articles

"Defibrotide-Free" Regimen As an Alternative Management of Late-Onset Severe Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation Shows Impressive Responses

Feng Chen, MD PhD, Yangmin Zhang, MD PhD, Zhaoyue Wang, PhD, Depei Wu, MD PhD

Blood (2017) 130 (Supplement 1): 5472.

https://doi.org/10.1182/blood.V130.Suppl_1.5472.5472

Published: 2017

Journal Articles

Low-Dose Decitabine Improves Platelet Recovery in Patients with Isolated Thrombocytopenia after HSCT

Yue Han, MD, Yaqiong Tang, Ying Zhao, Man Huang, Jia Chen, Jiaqian Qi, Ying Wang, Xiaojin Wu, Xiao Ma, Feng Chen, Xuefeng He, MD, Changgeng Ruan, MD PhD, Depei Wu, MD PhD

Blood (2016) 128 (22): 3388.

https://doi.org/10.1182/blood.V128.22.3388.3388

Published: 2016

Journal Articles

HLA-Haploidentical Donors Seem to be Not Inferior to HLA-Identical Sibling Donors for Hematopoietic Stem Cell Transplantation of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)?

Feng Chen, Depei Wu, MD PhD, XiaoWen Tang, MD, Miao Miao, Chengcheng Fu, Huiying Qiu, Shengli Xue, Xiao Ma, Zhengming Jin

Blood (2016) 128 (22): 5867.

https://doi.org/10.1182/blood.V128.22.5867.5867

Published: 2016

Journal Articles

Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome

Xiaowen Tang, MD, Jing Cao, Xiaojing Shi, Ling Ge, Aining Sun, PhD, Xiaming Zhu, Huiying Qiu, Zhengming Jin, Miao Miao, Chengcheng Fu, Xiao Ma, Feng Chen, Shengli Xue, Yue Han, MD, Mengxing Xue, Xinliang Mao, PhD, Depei Wu, MD PhD

Blood (2016) 128 (22): 5750.

https://doi.org/10.1182/blood.V128.22.5750.5750

Published: 2016

Journal Articles

Pre-Emptive Therapy with IFN-α-2b for Acute Leukemia Patients with High Risk of Relapsing Tendency Post Allo-HSCT

XiaoWen Tang, MD, Xiaoji Lin, Aijing Wang, Feng Chen, Xiao Ma, Aining Sun, PhD, Xiaming Zhu, Huiying Qiu, Zhengming Jin, Shengli Xue, Depei Wu, MD PhD

Blood (2016) 128 (22): 2250.

https://doi.org/10.1182/blood.V128.22.2250.2250

Published: 2016

Journal Articles

Superiority of Outcome for Patients with Late-Onset EBV Viremia Post Allogeneic Stem Cell Transplantation: A Chinese Multicenter Survey

Jia Chen, Feng Chen, Yang Xu, Ying Wang, Ziling Zhu, Jing Xu, Xiaoli Li, Chunmei Ye, Xiebing Bao, Aining Sun, PhD, Wu Depei, MD

Blood (2015) 126 (23): 5443.

https://doi.org/10.1182/blood.V126.23.5443.5443

Published: 2015

Journal Articles

Is HLA-Haploidentical Hematopoietic Stem Cell Transplantation a Valid Alternative Option for Patients with Combined Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia (AA/PNH Syndrome)?

Feng Chen, Wu Depei, MD, Xiaowen Tang, MD, Miao Miao, Chengcheng Fu, Huiying Qiu, Shengli Xue, Xiao Ma, Zhengming Jin

Blood (2015) 126 (23): 5535.

https://doi.org/10.1182/blood.V126.23.5535.5535

Published: 2015

Journal Articles

Weekly Low-Dose Rituximab As the Preemptive Management of Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Novel Strategy?

Feng Chen, Wu Depei, MD, Tao Tao, Wei Gong, Chunmei Ye, XiaoWen Tang, MD, Yue Han, MD, Huiying Qiu

Blood (2015) 126 (23): 3158.

https://doi.org/10.1182/blood.V126.23.3158.3158

Published: 2015

NARROW

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Sirolimus Plus Roxadustat in Patients with Pure Red Cell Aplasia: Results from a Prospective Multi-Center Clinical Trial

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory(R/R)Central Nervous System Lymphoma, Results from the Phase Ia Monotherapy of HZ-a-018-102 Study

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Venetoclax+Azacytidine Followed By Modified BuCy Conditioning Regimen for High Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia and High Risk Myelodysplastic Syndromes

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Comparison of Autologous Stem Cell Transplantation Versus Haplo-Identical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission

"Defibrotide-Free" Regimen As an Alternative Management of Late-Onset Severe Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation Shows Impressive Responses

Low-Dose Decitabine Improves Platelet Recovery in Patients with Isolated Thrombocytopenia after HSCT

HLA-Haploidentical Donors Seem to be Not Inferior to HLA-Identical Sibling Donors for Hematopoietic Stem Cell Transplantation of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)?

Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome

Pre-Emptive Therapy with IFN-α-2b for Acute Leukemia Patients with High Risk of Relapsing Tendency Post Allo-HSCT

Superiority of Outcome for Patients with Late-Onset EBV Viremia Post Allogeneic Stem Cell Transplantation: A Chinese Multicenter Survey

Is HLA-Haploidentical Hematopoietic Stem Cell Transplantation a Valid Alternative Option for Patients with Combined Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia (AA/PNH Syndrome)?

Weekly Low-Dose Rituximab As the Preemptive Management of Epstein-Barr Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Novel Strategy?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only